ELEVATE TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL

December 7-10, 2019; Orlando, Florida
Acalabrutinib with or without obinutuzumab significantly improved PFS compared with obinutuzumab plus chlorambucil.
Format: Microsoft PowerPoint (.ppt)
File Size: 208 KB
Released: December 11, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Gain key clinical insights quickly with this short slideset from CCO on CAR T-cell therapy for hematologic malignancies.

Michael R. Bishop, MD Daniel J. DeAngelo, MD, PhD Noopur Raje, MD Released: June 30, 2020

From Clinical Care Options (CCO), read an expert commentary on ibrutinib plus rituximab for frontline CLL treatment

Anthony Mato, MD Released: June 26, 2020

In this slideset from Clinical Care Options, Jeremy S. Abramson, MD, MMSc and Christopher R. Flowers, MD, MS highlight key data on the optimal use of BTK inhibitors

Jeremy S. Abramson, MD, MMSc Christopher R. Flowers, MD, MS Released: June 26, 2020

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL

Daniel J. DeAngelo, MD, PhD Released: June 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?